Education
About Us
Working with TipRanks
Follow Us
RegenXBio (RGNX)
NASDAQ:RGNX
RGNX Stock Chart & Stats
$11.16
-$0.26(-3.11%)
At close: 4:00 PM EST
$11.16
-$0.26(-3.11%)
Day’s Range― - ―
52-Week Range$5.04 - $16.19
Previous CloseN/A
Volume155.59K
Average Volume (3M)866.52K
Market Cap
$564.95M
Enterprise Value$774.29M
Total Cash (Recent Filing)$274.20M
Total Debt (Recent Filing)$268.14M
Price to Earnings (P/E)―
Beta2.29
Next Earnings
Mar 03, 2026EPS Estimate
-0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.20
Shares Outstanding50,623,085
10 Day Avg. Volume1,280,586
30 Day Avg. Volume866,519
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.47
Price to Sales (P/S)4.59
P/FCF Ratio-2.18
Enterprise Value/Market Cap1.37
Enterprise Value/Revenue4.80
Enterprise Value/Gross Profit9.60
Enterprise Value/Ebitda-6.45
Forecast
1Y Price Target
$36.25Price Target Upside224.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy In DuchenneRGX-202 has shown sustained functional improvements and no serious adverse events in Duchenne patients, which bolsters the case for approval and market uptake if results hold in confirmatory studies.
Manufacturing CapabilityIn-house, end-to-end manufacturing with high purity metrics and fill-finish capabilities enables scalable commercial supply and can reduce cost of goods, supporting launch readiness for multiple gene therapy franchises.
Regulatory MilestonesPivotal AFFINITY topline results could support an accelerated biologics license application, creating a clear regulatory pathway for the Duchenne program and potential commercialization value.
Bears Say
Binary Risk Profile And VolatilityHeavy dependence on trial readouts and regulatory filings gives the stock a binary risk profile, making it susceptible to sharp valuation swings based on single clinical or regulatory events.
Regulatory UncertaintyOngoing investigations into causality and shared biological risks between programs create regulatory uncertainty that may extend review timelines and complicate approval planning.
Safety Concern - Clinical HoldFDA clinical holds on multiple gene therapy programs after detection of an intracranial tumor have introduced material safety concerns that could impede development and investor sentiment.
RegenXBio News
RGNX FAQ
What was RegenXBio’s price range in the past 12 months?
RegenXBio lowest stock price was $5.04 and its highest was $16.19 in the past 12 months.
What is RegenXBio’s market cap?
RegenXBio’s market cap is $564.95M.
When is RegenXBio’s upcoming earnings report date?
RegenXBio’s upcoming earnings report date is Mar 03, 2026 which is in 31 days.
How were RegenXBio’s earnings last quarter?
RegenXBio released its earnings results on Nov 06, 2025. The company reported -$1.2 earnings per share for the quarter, beating the consensus estimate of -$1.282 by $0.082.
Is RegenXBio overvalued?
According to Wall Street analysts RegenXBio’s price is currently Undervalued.
Does RegenXBio pay dividends?
RegenXBio does not currently pay dividends.
What is RegenXBio’s EPS estimate?
RegenXBio’s EPS estimate is -0.77.
How many shares outstanding does RegenXBio have?
RegenXBio has 50,623,085 shares outstanding.
What happened to RegenXBio’s price movement after its last earnings report?
RegenXBio reported an EPS of -$1.2 in its last earnings report, beating expectations of -$1.282. Following the earnings report the stock price went down -3.79%.
Which hedge fund is a major shareholder of RegenXBio?
Currently, no hedge funds are holding shares in RGNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RegenXBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.25 (224.82% Upside)
$36.25 (224.82% Upside)
Blogger Sentiment
Bullish
RGNX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 30.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.0%
Last 30 Days ▲ 7.6%
Last 30 Days ▲ 7.6%
News Sentiment
Neutral
Bullish news 55%
Bearish news 45%
Bearish news 45%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.26%
12-Months-Change
Fundamentals
Return on Equity
-76.88%
Trailing 12-Months
Asset Growth
1.17%
Trailing 12-Months
Company Description
RegenXBio
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
RGNX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress and achievements in clinical development and financial positioning. However, there are regulatory challenges and uncertainties, particularly concerning international approvals and the use of external controls. Despite these challenges, the overall sentiment leans positive due to strong pipeline advancements and financial stability.View all RGNX earnings summariesRGNX Stock 12 Month Forecast
Average Price Target
$36.25
▲(224.82% Upside)
Technical Analysis
Solid Biosciences
―
Monopar Therapeutics Inc
―
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
9.43% Insiders
19.26% Mutual Funds
2.63% Other Institutional Investors
54.24% Public Companies and Individual Investors